Processa Pharmaceuticals (NASDAQ:PCSA) Shares Down 3.7% – Should You Sell?

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) traded down 3.7% during trading on Thursday . The stock traded as low as $1.29 and last traded at $1.30. 17,543 shares traded hands during trading, a decline of 99% from the average session volume of 1,241,034 shares. The stock had previously closed at $1.35.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Processa Pharmaceuticals in a report on Thursday, October 3rd.

Processa Pharmaceuticals Stock Performance

The firm has a market capitalization of $4.27 million, a PE ratio of -0.33 and a beta of 0.59. The firm’s 50-day moving average is $1.36 and its 200 day moving average is $1.67.

Processa Pharmaceuticals (NASDAQ:PCSA) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by ($0.03). As a group, equities analysts anticipate that Processa Pharmaceuticals, Inc. will post -3.78 earnings per share for the current year.

About Processa Pharmaceuticals

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.